WO2014134225A3 - Formulations comprising nutritive polypeptides and methods for treating cachexia, sarcopenia and muscle atrophy - Google Patents

Formulations comprising nutritive polypeptides and methods for treating cachexia, sarcopenia and muscle atrophy Download PDF

Info

Publication number
WO2014134225A3
WO2014134225A3 PCT/US2014/018807 US2014018807W WO2014134225A3 WO 2014134225 A3 WO2014134225 A3 WO 2014134225A3 US 2014018807 W US2014018807 W US 2014018807W WO 2014134225 A3 WO2014134225 A3 WO 2014134225A3
Authority
WO
WIPO (PCT)
Prior art keywords
polypeptides
methods
sarcopenia
formulations
muscle atrophy
Prior art date
Application number
PCT/US2014/018807
Other languages
French (fr)
Other versions
WO2014134225A2 (en
Inventor
Nathaniel SILVER
Michael HAMILL
Philip SAMAYOA
Jay HOU
Luke HAMM
David Berry
Shaila RAHMAN
Goeffrey MALTZAHN
Original Assignee
Pronutria, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pronutria, Inc. filed Critical Pronutria, Inc.
Publication of WO2014134225A2 publication Critical patent/WO2014134225A2/en
Publication of WO2014134225A3 publication Critical patent/WO2014134225A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/18—Peptides; Protein hydrolysates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1738—Calcium binding proteins, e.g. calmodulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Abstract

Nutritive polypeptides are provided herein. Also provided are various other embodiments including pharmaceutical formulations containing the nutritive polypeptides, nucleic acids encoding the polypeptides, recombinant microorganisms that make the polypeptides, vectors for expressing the polypeptides, methods of making the polypeptides using recombinant microorganisms, compositions that comprise the polypeptides, and methods of using the polypeptides to treat or prevent diseases, disorders and conditions associated with muscle wasting, and of using the polypeptides to improve and maintain muscle health.
PCT/US2014/018807 2013-02-26 2014-02-26 Nutritive polypeptides, formulations and methods for treating disease and improving muscle health and maintenance WO2014134225A2 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201361769429P 2013-02-26 2013-02-26
US201361769444P 2013-02-26 2013-02-26
US61/769,429 2013-02-26
US61/769,444 2013-02-26
US201361808650P 2013-04-05 2013-04-05
US61/808,650 2013-04-05

Publications (2)

Publication Number Publication Date
WO2014134225A2 WO2014134225A2 (en) 2014-09-04
WO2014134225A3 true WO2014134225A3 (en) 2014-11-20

Family

ID=50288297

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2014/018807 WO2014134225A2 (en) 2013-02-26 2014-02-26 Nutritive polypeptides, formulations and methods for treating disease and improving muscle health and maintenance

Country Status (1)

Country Link
WO (1) WO2014134225A2 (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8809259B2 (en) 2012-03-26 2014-08-19 Pronutria, Inc. Charged nutritive proteins and methods
MX2014011614A (en) * 2012-03-26 2015-04-08 Pronutria Inc Nutritive fragments and proteins with low or no phenylalanine and methods.
EP2831100A4 (en) 2012-03-26 2016-02-10 Pronutria Inc Nutritive proteins and methods
US9700071B2 (en) 2012-03-26 2017-07-11 Axcella Health Inc. Nutritive fragments, proteins and methods
BR112014023792A2 (en) 2012-03-26 2017-07-18 Pronutria Inc loaded nutrient proteins and methods
WO2015048333A2 (en) * 2013-09-25 2015-04-02 Pronutria, Inc. Nutritive polypeptides and formulations thereof, and methods of production and use thereof
CN104530232B (en) * 2014-12-23 2018-05-01 山东信得科技股份有限公司 The preparation method of duck virus hepatitis refined yolk antibody
WO2016205754A1 (en) 2015-06-19 2016-12-22 University Of Southern California Compositions and methods for modified nutrient delivery
WO2016205701A1 (en) 2015-06-19 2016-12-22 University Of Southern California Enteral fast access tract platform system
KR102348361B1 (en) * 2015-09-15 2022-01-11 (주)아모레퍼시픽 Composition for promoting differentiation of muscle cells containing amino acids
CN110028550B (en) * 2016-07-07 2022-08-05 华东理工大学 Antihypertensive peptide and antihypertensive protein and application thereof
CN108969888B (en) * 2017-06-02 2022-03-15 西艾丰控股公司 Wearable cardioverter defibrillator system using security tag to upload configuration data
JP7418896B2 (en) * 2018-04-18 2024-01-22 インジニアス イングリーディエンツ，エルピー Compositions and methods of use thereof to promote muscle growth and muscle function
CN108587998B (en) * 2018-05-17 2021-05-18 浙江大学 Exosome, preparation method of exosome and application of exosome in preparation of medicine for treating skin superficial tumors
CN110160958B (en) * 2019-05-23 2024-04-30 佛山科学技术学院 Optical coherence tomography device, imaging system and imaging method
CN110348747B (en) * 2019-07-15 2021-11-26 齐鲁工业大学 Intensive design method and system for product design
CN110652295B (en) * 2019-10-16 2022-04-26 中山大学 Method and system for quantifying individual difference of activation time sequence
CN110646418B (en) * 2019-10-24 2021-10-15 福建医科大学 Scandium ion rapid determination method using nanogold as developing probe
CN110922451A (en) * 2019-12-09 2020-03-27 福州大学 Porphyrin-modified cell-penetrating peptide and preparation and application thereof
CN112348833B (en) * 2020-11-06 2023-07-11 浙江传媒学院 Dynamic connection-based brain function network variation identification method and system
CN112822447B (en) * 2021-01-07 2023-04-14 云南电网有限责任公司电力科学研究院 Robot remote monitoring video transmission method and system based on 5G network
CN113151542B (en) * 2021-03-18 2023-05-05 西南林业大学 Development method and application of Huashansong genome SNP
CN113780412B (en) * 2021-09-10 2024-01-30 齐齐哈尔大学 Fault diagnosis model training method and system and fault diagnosis method and system
CN116554264B (en) * 2021-09-30 2023-11-28 中国农业大学 Oligopeptide separated from Rosa roxburghii, preparation method, oxidation resistance application and product thereof
CN113831185B (en) * 2021-10-27 2022-08-09 武汉爱民制药股份有限公司 Tianshima chestnut growth regulator and application thereof
CN114924587B (en) * 2022-05-27 2024-03-19 江苏科技大学 Unmanned aerial vehicle path planning method
CN117070454A (en) * 2023-10-18 2023-11-17 北京细胞治疗集团有限公司 Preparation method of CAR-T cells

Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08259461A (en) * 1995-03-24 1996-10-08 Snow Brand Milk Prod Co Ltd Lipometabolism improver
US6465432B1 (en) * 2000-08-28 2002-10-15 Kraft Food Holdings, Inc. Isolated antioxidant peptides form casein and methods for preparing, isolating, and identifying antioxidant peptides
US20040266689A1 (en) * 2002-01-16 2004-12-30 Mcmichael John Use of calmodulin to promote bone regeneration
WO2005000325A2 (en) * 2003-06-30 2005-01-06 Nestec S.A. Composition for treating and/or preventing dysfunctions associated with type 2 diabetes mellitus
US20050153019A1 (en) * 2000-08-22 2005-07-14 Fuchs Eileen C. Nutritional composition and method for improving protein deposition
US20090124560A1 (en) * 2006-04-21 2009-05-14 Masashi Morifuji Composition Containing Peptide as Active Ingredient
US20090170786A1 (en) * 2005-10-28 2009-07-02 Norman Alan Greenberg Methods for the use of branched chain amino acids
WO2011078654A1 (en) * 2009-12-24 2011-06-30 N.V. Nutricia Low-caloric high-protein nutritional composition for the stimulation of muscle protein synthesis
WO2013148328A1 (en) * 2012-03-26 2013-10-03 Pronutria, Inc. Nutritive proteins and methods
WO2013148330A1 (en) * 2012-03-26 2013-10-03 Pronutria, Inc. Nutritive fragments, proteins and methods
WO2013148332A1 (en) * 2012-03-26 2013-10-03 Pronutria, Inc. Nutritive fragments and proteins with low or no phenylalanine and methods
WO2013148329A1 (en) * 2012-03-26 2013-10-03 Pronutria, Inc. Charged nutritive proteins and methods
WO2013148331A1 (en) * 2012-03-26 2013-10-03 Pronutria, Inc. Charged nutritive fragments, proteins and methods

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08259461A (en) * 1995-03-24 1996-10-08 Snow Brand Milk Prod Co Ltd Lipometabolism improver
US20050153019A1 (en) * 2000-08-22 2005-07-14 Fuchs Eileen C. Nutritional composition and method for improving protein deposition
US6465432B1 (en) * 2000-08-28 2002-10-15 Kraft Food Holdings, Inc. Isolated antioxidant peptides form casein and methods for preparing, isolating, and identifying antioxidant peptides
US20040266689A1 (en) * 2002-01-16 2004-12-30 Mcmichael John Use of calmodulin to promote bone regeneration
WO2005000325A2 (en) * 2003-06-30 2005-01-06 Nestec S.A. Composition for treating and/or preventing dysfunctions associated with type 2 diabetes mellitus
US20090170786A1 (en) * 2005-10-28 2009-07-02 Norman Alan Greenberg Methods for the use of branched chain amino acids
US20090124560A1 (en) * 2006-04-21 2009-05-14 Masashi Morifuji Composition Containing Peptide as Active Ingredient
WO2011078654A1 (en) * 2009-12-24 2011-06-30 N.V. Nutricia Low-caloric high-protein nutritional composition for the stimulation of muscle protein synthesis
WO2013148328A1 (en) * 2012-03-26 2013-10-03 Pronutria, Inc. Nutritive proteins and methods
WO2013148330A1 (en) * 2012-03-26 2013-10-03 Pronutria, Inc. Nutritive fragments, proteins and methods
WO2013148332A1 (en) * 2012-03-26 2013-10-03 Pronutria, Inc. Nutritive fragments and proteins with low or no phenylalanine and methods
WO2013148329A1 (en) * 2012-03-26 2013-10-03 Pronutria, Inc. Charged nutritive proteins and methods
WO2013148331A1 (en) * 2012-03-26 2013-10-03 Pronutria, Inc. Charged nutritive fragments, proteins and methods

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
B. PENNINGS ET AL: "Whey protein stimulates postprandial muscle protein accretion more effectively than do casein and casein hydrolysate in older men", AMERICAN JOURNAL OF CLINICAL NUTRITION, vol. 93, no. 5, 2 March 2011 (2011-03-02), pages 997 - 1005, XP055122874, ISSN: 0002-9165, DOI: 10.3945/ajcn.110.008102 *
BURD NICHOLAS A ET AL: "Greater stimulation of myofibrillar protein synthesis with ingestion of whey protein isolate v. micellar casein at rest and after resistance exercise in elderly men", BRITISH JOURNAL OF NUTRITION, vol. 108, no. 6, September 2012 (2012-09-01), pages 958 - 962, XP002725705 *
MAGNE HUGUES ET AL: "Contrarily to whey and high protein diets, dietary free leucine supplementation cannot reverse the lack of recovery of muscle mass after prolonged immobilization during ageing", THE JOURNAL OF PHYSIOLOGY, 1 February 2012 (2012-02-01), pages no - no, XP055122532, ISSN: 0022-3751, DOI: 10.1113/jphysiol.2011.226266 *
P.C.B. LOLLO ET AL: "Effects of whey protein and casein plus leucine on diaphragm the mTOR pathway of sedentary, trained rats", FOOD RESEARCH INTERNATIONAL, vol. 49, no. 1, 1 November 2012 (2012-11-01), pages 416 - 424, XP055122890, ISSN: 0963-9969, DOI: 10.1016/j.foodres.2012.07.024 *

Also Published As

Publication number Publication date
WO2014134225A2 (en) 2014-09-04

Similar Documents

Publication Publication Date Title
WO2014134225A3 (en) Formulations comprising nutritive polypeptides and methods for treating cachexia, sarcopenia and muscle atrophy
WO2015048348A3 (en) Compositions and formulations for increasing renal function and treatment and prevention of renal diseases, and methods of production and use thereof
PH12018500586A1 (en) Farnesoid x receptor agonists and uses thereof
MX2021006581A (en) Bacteria engineered to treat diseases associated with hyperammonemia.
MX2021007268A (en) Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl] amino}acetic acid, compositions, and uses thereof.
WO2015048339A3 (en) Compositions and formulations for non-human nutrition and methods of production and use thereof
IL267210A (en) Amino acid compositions and methods for the treatment of muscle diseases and disorders
PH12016501441A1 (en) Chimeric alkaline phosphate-like proteins
MX2022009155A (en) Novel polymeric hgh prodrugs.
PH12018500315A1 (en) Fumagillol heterocyclic compounds and methods of making and using same
WO2016200614A3 (en) Bacteria engineered to treat diseases associated with hyperammonemia
MX2017009417A (en) Solid forms of 2-(5-(3-fluorophenyl)-3-hydroxypicolinamido)acetic acid, compositions, and uses thereof.
WO2017139697A8 (en) Bacteria engineered to treat diseases associated with hyperammonemia
EP3688021A4 (en) Use of metformin and analogs thereof to reduce ran protein levels in the treatment of neurological disorders
MX2017006437A (en) Spiro-isoquinoline-1,4'-piperidine compounds having multimodal activity against pain.
MX2022002635A (en) Angiopoietin-like 4 antibodies and methods of use.
MX2017014456A (en) Therapeutic uses of l-4-chlorokynurenine.
WO2016149659A3 (en) Antisense-induced exon exclusion in myostatin
MX2020009966A (en) Dosage forms and therapeutic uses l-4-chlorokynurenine.
TW201613977A (en) Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
MX2018000418A (en) Amide derivatives having multimodal activity against pain.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14710717

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 14710717

Country of ref document: EP

Kind code of ref document: A2